A Phase 1b, Open-label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 in Combination With Anti-PD-1 (Pembrolizumab) or Anti-PD-L1 (Atezolizumab) in Patients With Locally Advanced or Metastatic Solid Tumors

Trial Profile

A Phase 1b, Open-label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 in Combination With Anti-PD-1 (Pembrolizumab) or Anti-PD-L1 (Atezolizumab) in Patients With Locally Advanced or Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 May 2018

At a glance

  • Drugs Atezolizumab (Primary) ; NKTR 214 (Primary) ; Pembrolizumab (Primary)
  • Indications Bladder cancer; Malignant melanoma; Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms PROPEL
  • Sponsors Nektar Therapeutics
  • Most Recent Events

    • 10 May 2018 According to an Nektar Therapeutics media release, data will be presented at the American Society for Clinical Oncology (ASCO) 2018 Annual Meeting.
    • 01 Mar 2018 According to the Nektar Therapeutics media release, data from this study is expected in the second half of 2018.
    • 09 Nov 2017 Planned End Date changed from 30 May 2020 to 1 May 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top